Inventor · disambiguated record
Tongyao Liu
Also filed as: LIU TONGYAO
16 granted patents·31 pending applications·99 citations·filing 2009–2025
92Inventor score
Files withBIOVERATIV THERAPEUTICS INC39AMUNIX OPERATING INC3BIOGEN MA INC2JIANG HAIYAN2SCHELLENBERGER VOLKER1
Top patents by PatentIndex Score
47 records- 0194US10138291B2Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Nov 27, 2018·30 cites·36 claims
- 0293US11192936B2Factor VIII chimeric proteins and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Dec 7, 2021·10 cites·58 claims
- 0393US11091534B2Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Aug 17, 2021·8 cites·20 claims
- 0491US10421798B2Factor VIII compositions and methods of making and using sameSCHELLENBERGER VOLKER·Filed 2012·Granted Sep 24, 2019·16 cites·44 claims
- 0590US11286528B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 29, 2022·4 cites·14 claims
- 0690US11008561B2Optimized factor IX geneBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted May 18, 2021·4 cites·22 claims
- 0789US10745680B2Factor IX fusion proteins and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·6 cites·27 claims
- 0889US10548953B2Factor VIII-XTEN fusions and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2014·Granted Feb 4, 2020·6 cites·17 claims
- 0988US11370827B2Chimeric factor VIII polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Jun 28, 2022·5 cites·48 claims
- 1087US11753461B2Optimized factor VIII genesBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Sep 12, 2023·3 cites·15 claims
- 1186US12275970B2Optimized factor IX geneBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Apr 15, 2025·1 cites·15 claims
- 1282US10221455B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Mar 5, 2019·5 cites·25 claims
- 1375US12371747B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·17 claims
- 1475US2024083975A1Thrombin cleavable linker with xten and its uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1575US2023322900A1Factor viii compositions and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1675US2023019286A1Factor viii compositions and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1774US2024124555A1Optimized factor viii genesBIOVERATIV THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1872US12168776B2Nucleic acid molecules and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Dec 17, 2024·1 cites·13 claims
- 1972US2025179523A1Methods for the purification of viral vectorsBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2071US2025171805A1Nucleic acid molecules and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2170US2022275057A1Factor viii chimeric proteins and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2270US2022056108A1Factor viii complex with xten and von willebrand factor protein, and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2370US2024350672A1Nucleic acids encoding factor viii polypeptides with reduced immunogenicityBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2469US2025289869A1Factor viii chimeric proteins and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2569US2019315835A1Factor viii compositions and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2669US2025154489A1Optimized factor ix geneBIOVERATIV THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2768US2022106383A1Thrombin cleavable linker with xten and its uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2868US2023011438A1Chimeric factor viii polypeptides and uses thereofBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2967US2015038421A1Factor viii compositions and methods of making and using sameAMUNIX OPERATING INC·Filed 2014·Application pending·0 cites
- 3064US12173307B2Methods for the purification of viral vectorsBIOVERATIV THERAPEUTICS INC·Filed 2021·Granted Dec 24, 2024·0 cites·14 claims
- 3164US2016376344A1Factor viii compositions and methods of making and using sameAMUNIX OPERATING INC·Filed 2016·Application pending·0 cites
- 3263US2012027743A1Method for the Treatment of HemophiliaJIANG HAIYAN·Filed 2009·Application pending·0 cites
- 3363US2024294940A1Baculovirus expression systemBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3462US12364774B2Nucleic acid molecules and uses thereof for non-viral gene therapyBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Jul 22, 2025·0 cites·46 claims
- 3560US2013017997A1Factor VIII Compositions and Methods of Making and Using SameAMUNIX OPERATING INC·Filed 2012·Application pending·0 cites
- 3659US2021032616A1Factor ix fusion proteins and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3758US2020087379A1Factor viii compositions and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3858US2023091932A1Closed-end dna production with inverted terminal repeat sequencesBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3957US2016251408A1Thrombin cleavable linker with xten and its uses thereofBIOGEN MA INC·Filed 2014·Application pending·0 cites
- 4056US2023084036A1Optimized factor viii genesBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4155US2025269067A1Nucleic acid molecules and uses thereof for non-viral gene therapyBIOVERATIV THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4254US2022356490A1Baculovirus expression systemBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4351US2011286988A1FVIII Muteins for Treatment of Von Willebrand DiseaseJIANG HAIYAN·Filed 2009·Application pending·0 cites
- 4448US2021038744A1Use of lentiviral vectors expressing factor viiiBIOVERATIV THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4546US2020199626A1Use of lentiviral vectors expressing factor ixBIOVERATIV THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4644US2016229903A1Thrombin cleavable linkerBIOGEN MA INC·Filed 2014·Application pending·0 cites
- 4741US2021238259A1Factor ix fusion proteins and methods of making and using sameBIOVERATIV THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tongyao Liu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →